-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2021, under the background of the accelerated review of new drugs, the research and development of new anti-tumor drugs in China is still very hot
.
Statistics show that since the beginning of this year, more than 700 new drugs have been approved for clinical use in China, of which anti-tumor drugs account for more than half
.
Since November, there have been more than 100 clinically approved new drugs in China, of which nearly seven have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
From the perspective of companies with outstanding performance, Hengrui Pharmaceuticals, the "medical brother", is well-deserved
.
Since November, Hengrui Medicine and its subsidiaries have been approved for clinical trials of 6 types of anti-tumor drugs, including SHR-1701 injection, SHR-1909 injection, SHR-2002 injection, and apati mesylate.
Ni tablets, famitinib malate capsules, carrelizumab for injection, and a cardiovascular system drug SHR-2285 tablets have also been approved for clinical use
.
Among the six newly approved clinical anti-tumor drugs, carrelizumab is a blockbuster product.
Currently, the approved indications for this product include: first-line treatment of non-squamous non-small cell lung cancer and nasopharyngeal carcinoma, and second-line treatment of nose Pharyngeal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma of second-line and above, and relapsed and refractory classic Hodgkin’s lymphoma of third-line and above
.
It is reported that two new indications of carrelizumab combined with paclitaxel and cisplatin for the first-line treatment of advanced esophageal cancer and combined chemotherapy for the first-line treatment of advanced or metastatic squamous non-small cell lung cancer are currently in the approval stage and are expected Will be approved in the near future
.
Up to now, Hengrui Medicine has invested as much as 1.
776 billion yuan in research and development expenses for this product
.
The company's 2021 semi-annual report data shows that there are more than 10 single-drug or combination treatments under development for carrelizumab
.
Junshi Bio's performance is not inferior.
Since November, several oncology drugs including teriprilimab and JS012 injection have been approved for clinical use.
Among them, teripril is the first PD-1 monoclonal antibody to be marketed in China.
The indications currently approved for marketing include: second-line treatment of melanoma and urothelial cancer, and third-line treatment of nasopharyngeal carcinoma; in addition, new indications for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma are applied for marketing Was also approved at the end of November
.
It is reported that in terms of internationalization, Junshi Bio-Bio has submitted to the US FDA Terreplimumab combined with gemcitabine/cisplatin as the first-line treatment and single agent for patients with advanced recurrence or metastatic nasopharyngeal carcinoma for recurrence or The application for biological product license (BLA) for two indications of second-line and above treatment of metastatic nasopharyngeal carcinoma after platinum-containing treatment has been accepted
.
Junshi Biology’s 2021 semi-annual report data shows that Teriplimumab has carried out more than 30 clinical studies covering more than 15 indications in China, the United States and other countries, involving multiple cancer types
.
In addition to the deployment of first-line treatments, Junshi Biology is also developing perioperative adjuvant/neo-adjuvant treatments for multiple tumor types
.
It is worth mentioning that both carrelizumab and tereprizumab have been included in the medical insurance catalogue.
Among them, the indications of teriprizumab in the field of melanoma treatment will enter the medical insurance catalogue in December 2020.
In 2021, two new indications for nasopharyngeal carcinoma and urothelial cancer will be added to the new round of medical insurance; the indications for carrelizumab in 2020 include liver cancer, lung cancer, and Hodgkin Lymphoma and esophageal cancer
.
For the relevant patient groups, more new indications of these monoclonal antibodies are approved and entered into medical insurance, which is conducive to reducing the burden of patients' expenses
.
.
Statistics show that since the beginning of this year, more than 700 new drugs have been approved for clinical use in China, of which anti-tumor drugs account for more than half
.
Since November, there have been more than 100 clinically approved new drugs in China, of which nearly seven have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
From the perspective of companies with outstanding performance, Hengrui Pharmaceuticals, the "medical brother", is well-deserved
.
Since November, Hengrui Medicine and its subsidiaries have been approved for clinical trials of 6 types of anti-tumor drugs, including SHR-1701 injection, SHR-1909 injection, SHR-2002 injection, and apati mesylate.
Ni tablets, famitinib malate capsules, carrelizumab for injection, and a cardiovascular system drug SHR-2285 tablets have also been approved for clinical use
.
Among the six newly approved clinical anti-tumor drugs, carrelizumab is a blockbuster product.
Currently, the approved indications for this product include: first-line treatment of non-squamous non-small cell lung cancer and nasopharyngeal carcinoma, and second-line treatment of nose Pharyngeal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma of second-line and above, and relapsed and refractory classic Hodgkin’s lymphoma of third-line and above
.
It is reported that two new indications of carrelizumab combined with paclitaxel and cisplatin for the first-line treatment of advanced esophageal cancer and combined chemotherapy for the first-line treatment of advanced or metastatic squamous non-small cell lung cancer are currently in the approval stage and are expected Will be approved in the near future
.
Up to now, Hengrui Medicine has invested as much as 1.
776 billion yuan in research and development expenses for this product
.
The company's 2021 semi-annual report data shows that there are more than 10 single-drug or combination treatments under development for carrelizumab
.
Junshi Bio's performance is not inferior.
Since November, several oncology drugs including teriprilimab and JS012 injection have been approved for clinical use.
Among them, teripril is the first PD-1 monoclonal antibody to be marketed in China.
The indications currently approved for marketing include: second-line treatment of melanoma and urothelial cancer, and third-line treatment of nasopharyngeal carcinoma; in addition, new indications for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma are applied for marketing Was also approved at the end of November
.
It is reported that in terms of internationalization, Junshi Bio-Bio has submitted to the US FDA Terreplimumab combined with gemcitabine/cisplatin as the first-line treatment and single agent for patients with advanced recurrence or metastatic nasopharyngeal carcinoma for recurrence or The application for biological product license (BLA) for two indications of second-line and above treatment of metastatic nasopharyngeal carcinoma after platinum-containing treatment has been accepted
.
Junshi Biology’s 2021 semi-annual report data shows that Teriplimumab has carried out more than 30 clinical studies covering more than 15 indications in China, the United States and other countries, involving multiple cancer types
.
In addition to the deployment of first-line treatments, Junshi Biology is also developing perioperative adjuvant/neo-adjuvant treatments for multiple tumor types
.
It is worth mentioning that both carrelizumab and tereprizumab have been included in the medical insurance catalogue.
Among them, the indications of teriprizumab in the field of melanoma treatment will enter the medical insurance catalogue in December 2020.
In 2021, two new indications for nasopharyngeal carcinoma and urothelial cancer will be added to the new round of medical insurance; the indications for carrelizumab in 2020 include liver cancer, lung cancer, and Hodgkin Lymphoma and esophageal cancer
.
For the relevant patient groups, more new indications of these monoclonal antibodies are approved and entered into medical insurance, which is conducive to reducing the burden of patients' expenses
.
